PT Kalbe Farma Tbk.

Symbol: PTKFY

PNK

17.03

USD

Market price today

  • 0.0056

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 3.94B

    MRK Cap

  • 0.03%

    DIV Yield

PT Kalbe Farma Tbk. (PTKFY) Stock Price & Analysis

Shares Outstanding

231.28M

Gross Profit Margin

0.37%

Operating Profit Margin

0.12%

Net Profit Margin

0.09%

Return on Assets

383.70%

Return on Equity

0.13%

Return on Capital Employed

616.17%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. . Vidjongtius
Full-time employees:13108
City:Jakarta
Address:Gedung KALBE
IPO:2012-08-13
CIK:

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

General Outlook

In simple terms, PT Kalbe Farma Tbk. has 231.278 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.370% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.123%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.089%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 383.698% return, is a testament to PT Kalbe Farma Tbk.'s adeptness in optimizing resource deployment. PT Kalbe Farma Tbk.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.131%. Furthermore, the proficiency of PT Kalbe Farma Tbk. in capital utilization is underscored by a remarkable 616.166% return on capital employed.

Stock Prices

PT Kalbe Farma Tbk.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $29.1, while its low point bottomed out at $29.1. This variance in figures offers investors a lucid insight into the roller-coaster ride that is PT Kalbe Farma Tbk.'s stock market.

Liquidity Ratios

Analyzing PTKFY liquidity ratios reveals its financial health of the firm. The current ratio of 431.27% gauges short-term asset coverage for liabilities. The quick ratio (244.56%) assesses immediate liquidity, while the cash ratio (100.71%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio431.27%
Quick Ratio244.56%
Cash Ratio100.71%

Profitability Ratios

PTKFY profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 12.11% underscores its earnings before tax deductions. The effective tax rate stands at 26.18%, revealing its tax efficiency. The net income per EBT, 73.48%, and the EBT per EBIT, 98.53%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 12.29%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin12.11%
Effective Tax Rate26.18%
Net Income per EBT73.48%
EBT per EBIT98.53%
EBIT per Revenue12.29%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.31, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 2200794.13% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding245
Operating Cycle0.05
Receivables Turnover22007.94
Payables Turnover37633.27
Inventory Turnover11772.12
Fixed Asset Turnover14460.15
Asset Turnover4312.53

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.11, and free cash flow per share, -1793.01, depict cash generation on a per-share basis. The cash per share value, 1.16, showcases liquidity position.

cards.indicatorcards.value
Operating Cash Flow per Share1.11
Free Cash Flow per Share-1793.01
Cash per Share1.16
Free Cash Flow to Operating Cash Flow Ratio-1612.61
Cash Flow Coverage Ratio5.99
Short Term Coverage Ratio14.49
Dividend Payout Ratio0.03

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.35%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.03, we discern the balance between debt and equity financing. The long-term debt to capitalization, 1.75%, and total debt to capitalization, 2.95%, ratios shed light on its capital structure. An interest coverage of 34.88 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio2.35%
Debt Equity Ratio0.03
Long Term Debt to Capitalization1.75%
Total Debt to Capitalization2.95%
Interest Coverage34.88
Cash Flow to Debt Ratio5.99
Company Equity Multiplier1.29

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 131655.87, provides a glimpse into top-line earnings distributed across each share. Net income per share, 11962.86, reflects the portion of profit attributed to each share. The book value per share, 92610.79, represents the net asset value distributed per share, while the tangible book value per share, 92154.99, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share131655.87
Net Income Per Share11962.86
Book Value Per Share92610.79
Tangible Book Value Per Share92154.99
Shareholders Equity Per Share92610.79
Interest Debt Per Share3033.13
Capex Per Share-5097.64

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 1558272.86%, indicates top-line expansion, while the gross profit growth, 1546968.31%, reveals profitability trends. EBIT growth, 1298207.69%, and operating income growth, 1298207.69%, offer insights into operational profitability progression. The net income growth, 1211241.27%, showcases bottom-line expansion, and the EPS growth, -20.41%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth1558272.86%
Gross Profit Growth1546968.31%
EBIT Growth1298207.69%
Operating Income Growth1298207.69%
Net Income Growth1211241.27%
EPS Growth-20.41%
EPS Diluted Growth-20.41%
Weighted Average Shares Growth-0.56%
Weighted Average Shares Diluted Growth-0.56%
Dividends per Share Growth8.35%
Operating Cash Flow Growth122.49%
Free Cash Flow Growth-4207992.85%
10-Year Revenue Growth per Share1930589.48%
5-Year Revenue Growth per Share1930589.48%
3-Year Revenue Growth per Share1949720.19%
10-Year Operating CF Growth per Share7.61%
5-Year Operating CF Growth per Share7.61%
3-Year Operating CF Growth per Share-33.01%
10-Year Net Income Growth per Share1583862.19%
5-Year Net Income Growth per Share1583862.19%
3-Year Net Income Growth per Share1498059.80%
10-Year Shareholders Equity Growth per Share1895873.79%
5-Year Shareholders Equity Growth per Share1895873.79%
3-Year Shareholders Equity Growth per Share1747031.94%
10-Year Dividend per Share Growth per Share46.15%
5-Year Dividend per Share Growth per Share46.15%
3-Year Dividend per Share Growth per Share46.15%
Receivables Growth1824259.51%
Inventory Growth1476401.50%
Asset Growth1541332.62%
Book Value per Share Growth1639665.86%
Debt Growth821939.32%
R&D Expense Growth3835134.06%
SGA Expenses Growth995007.90%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 58,947,646,818,475.84, captures the company's total value, considering both debt and equity. Income quality, 1.07, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.02, gauges operational efficiency, while the research and development to revenue, 2.06%, highlights investment in innovation. The ratio of intangibles to total assets, 6.68%, indicates the value of non-physical assets, and capex to operating cash flow, -610687.87%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value58,947,646,818,475.84
Income Quality1.07
Sales General and Administrative to Revenue0.02
Research and Development to Revenue2.06%
Intangibles to Total Assets6.68%
Capex to Operating Cash Flow-610687.87%
Capex to Revenue-3.87%
Capex to Depreciation-2462291.26%
Graham Number157884.50
Return on Tangible Assets10.96%
Graham Net Net30602.15
Working Capital12,674,555,555,935
Tangible Asset Value21,313,440,435,725
Net Current Asset Value11,980,177,928,752
Average Receivables2,814,320,105,016.5
Average Payables845,424,130,869
Average Inventory3,396,219,898,974.5
Days Sales Outstanding67
Days Payables Outstanding33
Days of Inventory On Hand133
ROIC12.84%
ROE0.13%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.79, and the price to book ratio, 2.79, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -0.01, and price to operating cash flows, 15.32, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.79
Price to Book Ratio2.79
Price Cash Flow Ratio15.32
Price Fair Value2.79
Price to Operating Cash Flow Ratio15.32
Price to Free Cash Flows Ratio-0.01
Price to Tangible Book Ratio2.87
Enterprise Value to Sales1.94
Enterprise Value Over EBITDA14.72
EV to Operating Cash Flow305338.94
Earnings Yield4.49%
Free Cash Flow Yield-1.91%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of PT Kalbe Farma Tbk. (PTKFY) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 0.006 in 2024.

What is the ticker symbol of PT Kalbe Farma Tbk. stock?

The ticker symbol of PT Kalbe Farma Tbk. stock is PTKFY.

What is company IPO date?

IPO date of PT Kalbe Farma Tbk. is 2012-08-13.

What is company current share price?

Current share price is 17.030 USD.

What is stock market cap today?

The market cap of stock today is 3938665975.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 13108.